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Introduction. The aim of this study is to compare outcomes in three groups of STS patients treated in our specialist centre: patients
referred immediately after an inadequate initial treatment, patients referred after a local recurrence, and patients referred directly,
prior to any treatment. Patients and methods. We reviewed all our nonmetastatic extremity-STS patients with a minimum follow-
up of 2 years. We compared three patient groups: those referred directly to our centre (group A), those referred after an inadequate
initial excision (group B), and patients with local recurrence (group C). Results. The study included 174 patients. Disease-free
survival was 73%, 76%, and 28% in groups A, B, and C, respectively (P < .001). Depth, size, and histologic grade influenced
the outcome in groups A and B, but not in C. Conclusion. Initial wide surgical treatment is the main factor that determines local
control, being even more important than the known intrinsic prognostic factors of tumour size, depth, and histologic grade. The
influence on outcome of initial wide local excision (WLE), which is made possible by referral to a specialist centre, is paramount.
Copyright © 2009 Juan F. Abellan et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction
Soft tissue sarcomas (STSs) are a heterogeneous group of
tumours that derive from mesodermal tissue and can occur
anywhere in the body, although most are in the extremities
(59%), trunk (19%), retroperitoneum (15%), or head and
neck (9%) [1]. STSs are rare, representing only 1% of
malignant tumours in adults [2], but are often aggressive
neoplasms with the potential to recur after resection and to
spread systemically.
The main prognostic factors are intrinsic to the tumour:
histologic grade, depth, and tumour size; however, advanced
patient age and presence of metastases at diagnosis also affect
the outcome [3]. Surgery in the form of wide local excision
(WLE) is the primary treatment strategy, the goal being to
completely resect the tumour [4]. Local control of STS is
largely dependent on such surgery, and so any patient with
a lump that might possibly be a sarcoma—a lump bigger
than 5 cm, extending down to the fascia, growing in size, or
causing pain—should be referred to an appropriate specialist
centre, where diagnosis and treatment will be performed in
accordance with oncological criteria [5]. In most developed
countries, routine referral of patients with such lumps
is prescribed by well-defined guidelines. However, in our
country, there is no specific protocol in this respect, and
consequently, many patients are attended to in nonspecialist
centres. The result is that these patients are referred for
definitive treatment only after an initial inadequate excision
(IIE) has been performed or after subsequent diagnosis of
local recurrence. An IIE is also referred to as a whoops
procedure: the surgeon does not realise that the lump is
a sarcoma until receiving the pathologist’s report on the
material that has already been excised [5].
Patients subjected to an IIE usually need further surgery,
which increases the morbidity of the treatment. In addition,
there is evidence that insufficient resection increases the
risk of local recurrence [6], and it is well established that
local recurrence increases the risk of further local events.
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There is, however, little published information about the
local recurrence rate in whoops cases and even less on survival
rates. The aim of this study is to compare outcomes in
three groups of STS patients treated in our specialist centre,
patients referred after a whoops procedure, patients referred
after a local recurrence; and patients referred directly to our
centre for a definitive diagnosis.
2. Patients andMethods
We reviewed all patients with a minimum follow-up of two
years who had been treated for STS in our hospital between
1983 and 2006. We excluded cases of extraskeletal Ewing’s
Sarcomas, of STS when located anywhere other than in the
extremities, and of patients with metastases at the time of
diagnosis.
Patients were assigned to one of the following three
groups: group A, the virgin STS group, comprised those
who had been referred directly to and first diagnosed at our
hospital; group B, whoops cases, included patients who had
been referred to us immediately after an IIE; and group C,
the local-recurrence group, included patients referred after
having one or more local recurrences.
In all cases, all resected specimens had been examined
histologically and the tumour had been evaluated as high
or low grade. For group B patients, findings of residual
tumour had been noted. From our records of each patient,
the following data at the time of diagnosis were collected:
gender, age, and tumour characteristics (size, depth, and
histologic grade). For group C patients, we also assessed
depth and histologic grade of the primary tumour; in most
cases of group C, it was not possible to determine the
primary tumour size. In accordance with the criteria of the
American Joint Commission on Cancer Staging of STS [7],
we regarded tumours of 5 cm or less as small and those of
over 5 cm as big; tumours above the fascia were regarded
as superficial and those invading or beneath the fascia were
regarded as deep; neoplasms that were well- or moderately
well-differentiated as low grade and those that were poorly-
or un-differentiated as high grade. For patients who had been
previously operated on at another hospital (groups B and C
patients), we noted any evidence that indicated disregard of
basic oncologic surgery rules on the part of the surgeon, such
as scar orientation.
Outcomes were analysed in terms of disease-free survival
(DFS) and overall survival. Other outcome events, such as
local recurrence and distant metastases, were not assessed.
In this context of outcome events, for group C patients, we
use the term local recurrence to refer to any recurrence after
the surgical treatment at our institution (as opposed to the
recurrence that led to referral).
2.1. Statistical Methods. The Chi-square test was used to
compare phenotype frequencies between groups (diagnostic
categories; tumour grade, depth, and size; and metasta-
sis/relapse status). A multivariate survival analysis (stepwise
Cox regression) including prognostic factors (depth, grade,
and size) between groups A and B was performed.
Overall survival and disease-free survival data were
expressed as Kaplan-Meier curves, and groups were com-
pared by means of the logrank test (Mantel-Cox test). The
statistical analysis was performed with the SPSS software
v15.0 (SPSS, Statistical Package for the Social Sciences,
Chicago, IL; USA). In all cases statistical significance was
defined as P < .05.
3. Results
3.1. Patients. We treated a total of 236 STS patients between
1983 and 2006. Of them, 209 involved tumours in the
extremities. We excluded 25 patients with metastases at
diagnosis and 10 cases of extraskeletal Ewing’s Sarcoma. The
cases analysed then numbered were 174.
The mean age of these patients was 43.74 years, with
a standard deviation (SD) of 18.8 years. Mean follow-up
was 91.95 months (SD, 80.16 months), with no differences
between the three groups and a minimum follow-up of two
years.
Of the 174 cases, 57% were in group A, 22% were in
group B (Figure 1), and 21% were in group C (Figure 2).
Basic group characteristics are shown in Table 1.
3.2. Treatment. Patients were treated by surgery: radical exci-
sion with curative intention. Amputation as a primary ther-
apeutical procedure was not performed. Wide local excision
was complemented by radiation therapy and chemotherapy
as standard treatment of deep, big, and/or high-grade STS.
Of such patients, only 30% did not receive chemotherapy,
because of a contraindication to the procedure (such as car-
diologic disease). We now complement external radiotherapy
with brachytherapy, but, in the patients treated between
1983 and 2001, we used an intraoperative boost dose of
radiotherapy to the same end.
Histologic analysis detected malignant cells in all the
specimens from patients in groups A and C and residual
tumour cells in 40% of specimens from group B cases.
Analysis of previous operations, biopsies, or excisions
suggested that oncologic surgery rules were frequently
disregarded: in 39% of group B patients and 30% of group
C patients. The most frequent indicator of disregard was an
inappropriate transversal approach incision (Figure 1(b)).
3.3. Outcome
Local Recurrence. Overall, local recurrence occurred in 21%
of patients. The rates in groups A and B were 10% and 13%,
respectively (P = .608); in group C the rate was 59%. This
difference, A + B versus C, was statistically significant and
was not related with depth and histologic grade (Table 2).
Metastatic Disease. Overall, 27% of the patients suffered
metastatic disease: 22% in group A, 16% in group B, and
51% in group C (Table 3). The higher rate for group C
patients was statistically significant and was independent of
both depth and grade of the tumour.
Sarcoma 3
44 M 77/9781
11/10/99
10:15
L
2
1
1
(a) (b)
Figure 1: (a) Axial thigh T2-MR showing a hyperintense mass in the posterior aspect of the thigh. (b) Clinical image showing the wrong
incision (black arrows) performed to excise the lump with the preoperative diagnosis of a benign lump. Histologic analysis established that
the mass was a sarcoma; the excision had thus been a whoops procedure.
H
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Figure 2: (a) An example of the few patients in group C for whom we have data about the primary lump. Thigh T1-MR, showing a
subcutaneous lump (Malignant Fibrous Histiocytoma) in the groin. The mass was excised, in another hospital, without regard for basic
oncologic rules. (b) Clinical image showing how we first encountered the patient, who had suffered multiple local recurrences.
Table 1: Data on size, depth, and grade in the different STS groups considered.
N Age (SD) Size (%) Depth (%) Grade (%)
174 43.74 (18.7) ≤5 >5 1Sup. Deep Low High
Group A 99 46.17 (18.4) 14 (14) 85 (86) 17 (17) 82 (83) 34 (34) 65 (66)
Group B 38 35 (18.2) 16 (42) 22 (58) 15 (39) 23 (61) 12 (32) 26 (68)
A versus B
P-value2
.002 <.001 .006 .759
Group C 37 46.22 (17.9) 3NA NA 2 (5) 35 (95) 18 (49) 19 (51)
A + B versus C
P-value
.005 — .001 .230
1
Sup.: superficial; 2the statistical analysis does not include group C; 3NA: not available.
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Table 2: Characteristics of the STS in the different groups according to recurrence.
Recurrence (%)
Depth (%) Grade (%)
Superficial Deep Low High
Group A 10 (10) 0 (0) 10 (100) 3 (30) 7 (70)
Group B 5 (13) 2 (40) 3 (60) 2 (40) 3 (60)
Group C 122 (59) 10 (46) 22 (54) 11 (50) 11 (50)
A versus B
P-value2
.608
A + B versus C
P-value
<.0001
1
This value refers to the rate of local recurrence after treatment in our institution.
2The statistical test does not include group C.
Table 3: Characteristics of the STS in the different groups according to metastasis.
Metastasis (%)
Depth (%) Grade (%)
Superficial Deep Low High
Group A 22 (22) 6 (27) 16 (73) 5 (23) 17 (77)
Group B 6 (16) 2 (33) 4 (67) 0 (0) 6 (100)
Group C 19 (51) 10 (50.0) 18 (51.4) 8 (42) 11 (58)
A versus B
P-value1
.403
A + B versus C
P-value
<.001
1
The statistical test does not include group C.
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Figure 3: Kaplan-Meier curve of disease-free survival rates. Groups
have been stratified according to tumour depth.
Survival. The rate of DFS was significantly lower in group C
patients, 28%, than those in groups A and B patients, 73%
and 76%, respectively (P < .0001). As shown in the Kaplan-
Meier curves of Figure 3, when considering only cases with
superficial STS, the highest disease-free survival rates were
for patients in group A. Multivariate analysis between groups
A and B showed that only tumour size statistically influenced
both overall and disease-free survival (P = .024).
With regard to overall survival, the mean for the three
groups was 69.9%, with no significant differences between
the groups (P > .05) (Figure 4). The overall survival of
group B patients is apparently, but not statistically, higher.
As with DFS, this is because the whoops STS were mostly
subcutaneous (Table 1).
4. Discussion
The current view is that STS treatment in a referral
centre, where diagnosis and treatment follow oncologic rules,
improves results in terms of both quality of life and survival
[3]. However, because soft tissue sarcomas (STSs) are rare—
on average a family doctor will see just one case for every
24 years of practice [8]—malignancy is not always suspected,
with the consequence that referral is delayed, or the patient
is treated in a nonspecialist centre.
The retrospective series of patients we present and
analyse here does not provide a representative sample of
STSs. This is indicated, for example, by the fact that between
1980 and 2006 our centre treated over 1000 bone sarcomas
but less than 300 STSs in the extremities.
Without a biopsy, an STS, especially if it is subcutaneous
and small, is sometimes misconstrued as a benign mass and
surgically excised without the adequate margins for a malig-
nant mass. Histologic study of the resected lump overturns
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the preoperative diagnosis and establishes the previously
unsuspected diagnosis of sarcoma. Such an incident is known
as inadequate initial excision (IIE) and a whoops procedure [5].
In the 1990s, between 19% and 53% of the new patients seen
in sarcoma centres were referred after an IIE [9–11].
To ensure early diagnosis and management of all sus-
pected STS cases, developed countries such as the UK drew
up referral guidelines [12] according to which any patient
with a lump suspected of being an STS or with a recurrence
of a previously excised lump must be referred to a specialist
centre with an appropriate multidisciplinary approach; a
lump should be suspected of being an STS if it is bigger than
5 cm, deeper than the fascia, growing in size, or causing pain.
In our practice, we still see patients referred after
whoops procedures. These patients are often distressed by the
unexpected diagnosis and, like their physicians, concerned
about the prognosis and further management of the disease.
Wide local excision (WLE) is the correct primary
treatment strategy for extremity STS. The overall approach
to treatment should be multidisciplinary: with a specialist
sarcoma surgeon, radiologists, pathologists, and clinical
oncologists [3]. Recent multimodal strategies combining
surgery and radiotherapy, complemented or not with
chemotherapy, have enabled WLE to replace amputation as
standard treatment without increasing local recurrence rates
or decreasing overall survival [13]. In recurrent STS, some
authors consider that amputation may decrease the local
recurrence rate [14, 15]; benefits in overall survival have not
been reported.
For patients with nonmetastatic STS, overall survival is
50%–70% [4, 16]. There are three main prognostic factors:
tumour size, histologic grade, and depth. In addition, some
authors have recently found advanced patient age to be a
prognosis factor [3].
In our study we categorized patients into three groups
to determine how an initial inadequate treatment of an STS
affected the outcome. We found that patients diagnosed in
and treated at our centre (group A) and patients referred
immediately after an IIE (group B) presented similar results
in terms of local recurrence rate, metastasis rate, disease-free
survival, and overall survival (Tables 2 and 3, Figures 3 and
4). Given that some of the patients were initially treated in
another centre, data on surgical margins were not always
available. This important factor regarding local control has
not been therefore considered in the present analysis.
Paradoxically, patients treated after an initial whoops
event had better outcomes than those who were diagnosed
and treated directly in our institution (Figure 3). This
finding, also reported by Lewis et al. [9], is explained by the
fact that big, deep lumps are usually referred whilst the small,
subcutaneous STSs are more likely to be misconstrued as
benign and only to be discovered after a whoops event. In our
series, 83% of virgin cases and 60% of whoops cases were deep
tumours. When survival is calculated for primary tumours of
equal depth, our virgin-STS patients showed better outcomes
than the whoops patients (Figure 3).
Our third group was for patients with one or more
recurrences, with or without a whoops event, prior to
treatment at our centre. Surgical treatment of these patients
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Figure 4: Kaplan-Meier graph showing overall survival comparing
the three groups.
was complemented with an established combined treatment
including perfusions of isolated limbs with tumour necrosis
factor and melphalan [17] or perioperative high-dose-rate
brachytherapy [18, 19]. The local recurrence and metastasis
rates for group C (after treatment in our centre) were
worse than the rates for groups A and B (Figure 3). This
was the case despite the proportion of low grade STSs at
primary presentation being higher in group C (Table 1). The
results of group C are shown without statistical comparison
with groups A and B, because they represent a different
clinical situation (primary versus relapsed tumours). The
poor outcome in these patients could be explained by
supposing that the initial STSs were more aggressive, but we
believe that the real cause of the low disease-free survival is
related to inadequate initial surgical excision. There are two
reasons to justify this position. First, one third of the patients
in this group presented scars indicative of wrong incisions
(Figure 1(b)). The implied disregard of basic oncologic
rules suggests that the surgeon was not used to treating
malignant lesions, and that it is unlikely that WLE was
performed. Second, overall survival in this group is above
55% (Figure 4): such high overall survival is not compatible
with a supposition of STS aggressiveness.
The big question when faced with an IIE patient
is whether further surgery is necessary. We believe that
the answer is yes. Previous reports show that unplanned
excisions of STS tend to be incomplete [6, 10, 20–23],
and residual tumour cells were commonly found (35%–
77% of cases). Our results support these findings: Forty
percent of our IIE patients showed evidence of residual
disease. Wide excision of residual tumour after an IIE is,
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therefore, imperative to achieve local control of the disease.
In our study, whoops patients who we reoperated on with
wide excision had similar survival outcomes to patients
who were diagnosed and treated directly at our centre.
Good results after reexcision of an IIE have been reported
for other specialist centres [5, 6, 20, 22]. However, to
our knowledge this is the first study to compare a single
centre’s results with IIE reexcisions and with both direct
treatments and treatments of local recurrence secondary to
an IIE. Our results indicate that initial WLE is the main
factor determining local control; this factor has a huge
influence on the outcome, even greater than that of the
intrinsic prognostic factors (histologic grade, tumour size,
and depth).
Although survival after wide reexcision in a whoops
patient is similar to that for a direct WLE patient, the
morbidity rate is higher for the former because, first, at
least one additional operative intervention (the reexcision)
is needed; second, a greater volume of tissue is resected;
third, a larger field is radiated; and fourth, soft tissue
coverage procedures are more frequent [24]. In our study,
95% of reexcised whoops patients needed adjuvant treatment.
Therefore, to avoid complications, it is important that all
patients with suspicious lumps be referred to a specialist
centre. The situation with STS is the same as that asserted
by Wafa and Grimer with regard to bone sarcoma [25]: there
is no role for occasional surgeons; the first surgical excision is
critical in the prognosis and outcome for these patients, and
thus they must be treated in specialist centres.
5. Conclusions
A patient with a lump which in any way raises a suspicion
of STS should be referred to a specialist centre, where
a multidisciplinary team with good experience of such
infrequent lesions can assess the patient and determine the
best treatment.
The unplanned excision of a malign mass, the whoops
procedure, should be immediately followed by wide reexci-
sion, which in our study resulted in survival rates similar to
those for patients operated on directly with WLE. Reoperated
patients suffered more radiotherapy related complications
and a general increase in the morbidity rate. Patients pre-
senting a local recurrence after an IIE had worse outcomes,
especially in terms of disease-free survival.
Initial wide surgical treatment is the main factor that
determines local control, being even more important than
the known intrinsic prognostic factors of tumour size,
depth, and histologic grade. The influence of initial WLE on
outcome is paramount. However, these conclusions should
be interpreted with caution, because the number of patients
in each group is relatively small and important differences
might be undetected.
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